Showing 2111-2120 of 3223 results for "".
- Allergan Receives FDA Approval for Durysta, the First Sustained-Release Implant for Glaucomahttps://modernod.com/news/allergan-receives-fda-approval-for-durysta-the-first-sustained-release-implant-for-glaucoma/2477351/Allergan announced that the FDA has approved the company’s new drug application (NDA) for Durysta (bimatoprost implant) 10 mcg for intracameral administration. With this approval, Durysta becomes the first intracameral, biodegradable sustained-release implant indicated to reduce IOP in pati
- AbbVie, Allergan Clear EU Merger Hurdle With GI Candidate Salehttps://modernod.com/news/abbvie-allergan-clear-eu-merger-hurdle-with-gi-candidate-sale/2477346/As AbbVie and Allergan wade through U.S. regulatory review of their pending $63 billion merger, the EU has given the pair hope their transaction will pass muster, according to a FiercePharma
- Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Dayhttps://modernod.com/news/aldeyra-therapeutics-to-provide-update-on-late-stage-clinical-development-pipeline-at-2020-research-development-day/2477322/Aldeyra Therapeutics on Monday hosted the 2020 Research & Development Day (R&D Day) with investors and financial analysts in New York City to present recent clinical development updates and market opportun
- Allergan to Present New Data for Investigational Bimatoprost Sustained-Release at American Glaucoma Society Annual Meetinghttps://modernod.com/news/allergan-to-present-new-data-for-investigational-bimatoprost-sustained-release-at-american-glaucoma-society-annual-meeting/2477323/Allergan will present new data from investigational Bimatoprost sustained-release (SR) at the annual meeting of the American Glaucoma Society (AGS) to be held in Washington, DC. Data from the phase 3 ARTEMIS studies will be presented during an oral session and wil
- Allergan, Sightsavers, and the IAPB Announce the “Keep Sight” Initiative to Address Glaucoma in Ganjam, Odishahttps://modernod.com/news/allergan-sightsavers-and-the-iapb-announce-the-keep-sight-initiative-to-address-glaucoma-in-ganjam-odisha/2477318/Allergan, Sightsavers, and the International Agency for the Prevention of Blindness (IAPB) announced the launch of its unique joint initiative, ‘Keep Sight India,’ a community-based glaucoma screening program to prevent glaucoma-related vision loss in Ganjam District, Odisha. The pilot kicked off
- AbbVie-Allergan Deal Foes Try Again to Spur an FTC Crackdownhttps://modernod.com/news/abbvie-allergan-deal-foes-try-again-to-spur-an-ftc-crackdown/2477311/AbbVie and Allergan’s megamerger is likely in the final stages of review after the pair agreed to offload three drugs, including IL-23 hopeful brazikumab. But a cadre of union and consumer groups say that’s not enough—and they’re taking another stab at turning regulators against
- Alcon Receives FDA Approval for OTC Pataday Once Daily Relief for Allergy Reliefhttps://modernod.com/news/alcon-receives-fda-approval-for-otc-pataday-once-daily-relief-for-allergy-relief/2477298/Alcon announced that Pataday Once Daily Relief (olopatadine hydrochloride ophthalmic solution 0.2%) and Pataday Twice Daily Relief (olopatadine hydrochloride ophthalmic solution 0.1%) have been approved by the FDA for sale over-the-counter (OTC) in the United States. The Pataday brand features th
- Certain Chronic Illnesses Tied to Increased Crash Risk for Elderly Drivershttps://modernod.com/news/certain-chronic-illnesses-tied-to-increased-crash-risk-for-elderly-drivers/2477296/Some older drivers with chronic health problems may cut back on driving but still be at increased risk of crashes, a recent study suggests, as reported by Reuters. Meanwhile, other drivers with medical issues may also be at higher
- Alexander van der Mey Named New CCO at Optimo Medical AGhttps://modernod.com/news/alexander-van-der-mey-named-new-cco-at-optimo-medical-ag/2477248/As of January 16, Alexander van der Mey assumed the role of chief commercial officer (CCO) position of Optimo Medical AG. In his new position, Mr. van der Mey is responsible for global marketing and sales. Mr. Van der Mey has studied business administration in Germany and the Netherlands.
- Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-announces-first-patient-enrolled-in-the-phase-3-invigorate-trial-in-allergic-conjunctivitis/2477243/Aldeyra Therapeutics announced enrollment of the first patient into the phase 3 INVIGORATE trial of topical ocular reproxalap in patients with allergic conjunctivitis. “Initiating enrollment in the INVIGORATE trial moves us closer to our goal of providing allergic conjunctivitis patients w